-

04:16:17 PM

XENE Stock News

XENE - Xenon Pharmaceuticals Inc

06/27/22 2:11 PM

Nasdaq : XENE

offering

Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold

RHEA-AI

neutral

06/22/22 10:27 PM

Nasdaq : XENE

offering

Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,868,854 common shares and, in lieu of common shares to certain investors,

RHEA-AI

neutral

06/22/22 4:02 PM

Nasdaq : XENE

offering

Xenon Pharmaceuticals Announces Proposed Public Offering

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that so

RHEA-AI

neutral

06/22/22 4:01 PM

Nasdaq : XENE

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction New XEN1101 OLE data demonstrates continued seizure reduction exceeding 70% at 3 months in OLE and exceeding

RHEA-AI

neutral

06/21/22 7:00 AM

Nasdaq : XENE

clinical trial

Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial Plans to initiate

RHEA-AI

very positive

06/01/22 4:01 PM

Nasdaq : XENE

conferences

Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held

RHEA-AI

neutral

05/10/22 4:01 PM

Nasdaq : XENE

earnings

Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD Conference Call at 4:30 pm ET Today

RHEA-AI

positive

05/03/22 4:01 PM

Nasdaq : XENE

earnings

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10,

RHEA-AI

neutral

05/03/22 8:00 AM

Nasdaq : XENE

clinical trial

Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the initiation of a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical study – called the “X-NOVA” clinical

RHEA-AI

neutral

04/25/22 4:01 PM

Nasdaq : XENE

conferences

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company today announced that Xenon’s management team will participate in the following investor conferences: Jefferies Biotech on the Bay Summit

RHEA-AI

neutral

1 2 3 4 5 6 Next